Q3 2025 Management View CEO Marianne De Backer highlighted the completion of enrollment in ECLIPSE 1, Vir’s first registrational Phase III study for hepatitis delta, ahead of internal projections. She ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback